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BACKGROUND: Lung cancer is known as the top cancer killer in most developed countries. However, there is currently no promising
diagnostic or prognostic biomarker for lung cancer. This study aims to discover non-invasive differential markers in the serum of lung
cancer patients, to determine the protein identity of the candidate biomarker(s), and to investigate any clinical implication of the
biomarker(s) concerned.
METHODS: Blood specimens were collected from 154 pre-operative patients with lung cancer and 35 healthy blood donors with no
evidence of lung cancer. Fractionated serum samples were processed by surface-enhanced laser desorption/ionisation time-of-flight
mass spectrometry (MS). Candidate biomarker was identified using sodium dodecyl sulphate polyacrylamide gel electrophoresis and
tryptic digestion followed by tandem MS fragmentation analysis, which was subsequently validated with immunoassay.
RESULTS: A differential protein with m/z 11.6kDa was detected and identified as an isoform of human serum amyloid A (SAA). It was
significantly increased by 1822% in lung cancer patients when compared with the healthy controls, which gave an area under the
receiver operator characteristic curve of 0.88. In addition, the protein was also significantly elevated by 77% in lung cancer patients
with survival o5 years when compared with patients with survival X5 years.
CONCLUSION: There are several functions of the SAA protein, described in the context of inflammation, that are compatible with the
mechanism of tumour invasion and metastasis. Our study not only detected increased SAA level in the serum of lung cancer patients
but also identified that elevated SAA level may be a non-invasive biomarker useful for the prediction of lung cancer prognosis.
British Journal of Cancer (2010) 102, 1731–1735. doi:10.1038/sj.bjc.6605700 www.bjcancer.com
Published online 25 May 2010
& 2010 Cancer Research UK
Keywords: lung cancer; proteinchip; proteomics; SELDI-TOF-MS; serum amyloid A; serum biomarker
                                                   
Lung cancer is known as the top cancer killer in most developed
countries. Despite marked progress in the treatment, most patients
still die of the disease within several months to a few years. The
majority of lung cancer is diagnosed at a relatively late stage, and
recurrence is common even after optimal therapy. However, there
is currently no promising diagnostic or prognostic biomarker for
this lethal disease (Cho, 2007a, 2010a). Proteins are the workhorse
molecules of life. As proteome changes in response to cancer, it is
of great interest to medical researchers. There is hope that
oncoproteomics research may help to develop new approaches for
early cancer diagnosis, to determine the best therapies for
individual patients with specific types of cancer, and to predict
whether cancer will recur after treatment (Cho and Cheng, 2007;
Cho, 2007b; Cohen et al, 2008; Ga ´mez-Pozo et al, 2009; Han et al,
2009). In recent years, proteomics has been propelled by advances
in mass spectrometry (MS) that high-throughput protein profiling
enables large-scale screening of proteins within a small sample
volume (Cho, 2009). This study aims to use protein profiling for
the identification of serum biomarkers that can distinguish
patients with lung cancer from healthy controls, as well as
differentiate lung cancer patients between poor prognosis and
good prognosis, which may potentially provide non-invasive
biomarkers for the detection of lung cancer and the prediction
of survival in lung cancer patients.
MATERIALS AND METHODS
Serum samples
Human sera were obtained through hospital-approved protocols at
the Queen Elizabeth Hospital in Hong Kong from each non-fasting
individual with provision of informed consent indicating voluntary
participation. Specimens were collected from pre-operative
patients diagnosed with lung cancer (n¼154) and blood donors
with no evidence of lung cancer (n¼35). Information was
collected from each patient pertaining to age and gender. Healthy
controls were selected from an archive of blood samples on the
basis of matching for age, sex, minimum previous handling, and
time period of collection similar to the lung cancer group. The
average age±standard error of the mean (s.e.m.) for the lung
cancer patients was 65.5±0.9 years. Among these patients, 83.8%
were male (n¼129) and 16.2% were female (n¼25). Regarding
the stages of the disease, 55% (n¼85) of the patients were
diagnosed with early-stage lung cancer and 45% (n¼69) were
diagnosed with advanced-stage lung cancer. Within the cancer
samples, 34.4% were squamous-cell carcinoma samples (n¼53),
32.5% adenocarcinoma (n¼50), 8.4% other non-small-cell
lung cancer (n¼13), and 24.7% small-cell lung cancer (n¼38).
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allowed to clot for 30min to 1h at room temperature and was
centrifuged at 1500g for 10min. All sera were aliquoted and frozen
at  701C until thawed specifically for protein profiling.
Sample fractionation
To increase the detection of a larger number of peaks, as well as to
alleviate signal suppression effects on low-abundant proteins from
high-abundant proteins such as albumin, serum samples were
fractionated into six fractions containing proteins separated
roughly on the basis of their isoelectric points, as previously
described (Cho et al, 2007). Briefly, 20ml of each serum sample was
diluted during fractionation in 30mlo f5 0 m M Tris-HCl buffer
(pH 9) containing 9 M urea and 2% 3-((3-cholamidopropyl)
dimethylammonio)-1-propanesulfonate (CHAPS). A further dilu-
tion was made in 50mM Tris-HCl buffer (pH 9) containing 1 M urea
and 0.22% CHAPS. Serum samples were loaded onto each well of a
96-well filter plate pre-filled with a Q Hyper DF anionic exchange
sorbent (Ciphergen Biosystems, Fremont, CA, USA) and eluted in
a stepwise pH gradient using a Biomek 2000 liquid-handling robot
(Beckman Coulter, Fullerton, CA, USA), as described by the
manufacturer. The fractions contained the flow-through proteins
eluted with pH 7, 5, 4, and 3, and an organic buffer. Each of the six
fractions was collected twice and the two collections were pooled.
This helped to ensure the pH changes appropriately and also gave
greater reproducibility in the fractionation, as well as better
partitioning of proteins into their respective fractions.
Protein profiling
Fractioned serum samples were processed for surface-enhanced laser
desorption/ionisation time-of-flight (SELDI-TOF) MS (Ciphergen
Biosystems) analysis using the eight-spot weak cation exchange
(WCX2) ProteinChip (Ciphergen Biosystems) as previously
described (Au et al, 2008). Each sample was assayed in duplicate,
having duplicate samples randomly placed on different protein-
chips with the aid of a 96-well bioprocessor. A pooled quality
control sample prepared in the same manner was applied to
duplicate spots on each proteinchip used in the experiment as a
reproducibility control. To equilibrate the proteinchips, 150mlo f
binding buffer (100mM sodium acetate at pH 4) was added into
each well. The bioprocessor was sealed and incubated with the
samples at room temperature for 5min, with vigorous agitation on
a MicroMix 5 shaker (Diagnostics Products Corporation, NJ, USA).
The buffer was removed after vortexing. To bind samples onto the
proteinchips, 90ml of binding buffer (100mM sodium acetate at
pH 4) and 10ml of fractioned sample was added into each well and
vortexed for 30min at room temperature. A further 150mlo f
binding buffer (100mM sodium acetate at pH 4) was added into
each well and vortexed for 5min at room temperature. The excess
sera mixtures were discarded after vortexing. The proteinchips
were washed twice with de-ionised water and then removed from
the bioprocessor. A saturated solution of 1ml sinapinic acid
(Ciphergen Biosystems) in 50% (v/v) acetonitrile and 0.5% (v/v)
trifluoroacetic acid was applied twice to each spot and air dried for
10min between the applications. The proteinchips were air-dried
and analysed using a proteinchip reader PBS-IIc (Ciphergen
Biosystems) with acquisition up to 200kDa. Spectra were collected
by the accumulation of 232 shots at laser intensity 180 in a positive
mode. The protein masses were calibrated externally using the
all-in-one peptide standard (Ciphergen Biosystems).
Protein identification
The differential protein of interest between the cancer sera and
healthy controls was identified with sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and tryptic
digestion followed by tandem MS fragmentation analysis. Proteins
fractionated at organic solvent eluant from the anion exchange
filters were characterised by SDS-PAGE. The protein band
containing the desired biomarker was cut from the gel and
subjected to overnight tryptic digestion. Protein identification was
confirmed by tandem MS fragmentation analysis of the peptide
generated from the tryptic digest. Tandem MS fragmentation of the
peptide generated a set of tandem MS ion fingerprint data, which
was exported for database matching and subsequent identification
using the Mascot program (Matrix Science Inc, Boston, MA, USA).
Quantitative analysis of serum samples for serum amyloid A The
concentration of serum amyloid A (SAA) was determined in both
the lung cancer sera (n¼38) and the healthy control sera (n¼34)
using a commercially available immunoassay kit (BioSource,
Brussels, Belgium), and the analysis was performed according to
the manufacturer’s instructions.
Statistical analysis
The CiphergenExpress software version 3.0.6 (Ciphergen
Biosystems) was used to compare serum protein profiles to
discover peaks that were differentially expressed between two
comparable groups. To visualise the protein peaks that differed in
the majority of samples in one group compared with the majority
of samples in the other, principal components analysis (PCA) was
performed to reduce the dimensionality of the data set and to
identify new meaningful underlying variables with visualisation by
three-dimensional PCA display. Hierarchical clustering was also
conducted and visualised by heat map, a graphical representation
of the entire array in grid form with columns representing samples
and rows showing the mass-to-charge ratio (m/z) of protein peaks.
For univariate analysis, the average normalised intensity of each
peak was calculated for the comparable groups. The difference in
group means was reported as the percentage of change, that is, the
percentage of (average intensity of one group   average intensity
of the compared group)/average intensity of the compared group.
The comparison of P-values was analysed by the non-parametric
Mann–Whitney U-test; a peak was deemed to show a statistically
significant difference in group means if its P-value was o0.05. In
addition, the receiver operator characteristic analysis of each
protein peak was performed for the comparable groups, with the
area under the curve value calculated for each peak.
RESULTS
Serum protein profiling in lung cancer patients
A total of 245 peaks were detected with m/z ranging from 1 to
197kDa. Of these, 53 peaks were generated from fraction 1 (pH 9
and flow through), 43 peaks were generated from fraction 2 (pH 7),
28 peaks were generated from fraction 3 (pH 5), 38 peaks were
generated from fraction 4 (pH 4), 39 peaks were generated from
fraction 5 (pH 3), and 44 peaks were generated from fraction 6
(organic eluant).
Detection of lung cancer
Comparison of the protein profiles using three-dimensional PCA
(Figure 1A) and hierarchical clustering analysis (Figure 1B)
showed that the serum profiles of patients with lung cancer
(n¼154) could be separated from the healthy control group
(n¼35). There were 140 peaks with significant discriminatory
value at distinguishing the lung cancer sera from the healthy
control sera. The 10 most discriminating peaks were shown in
Table 1A.
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To discriminate the good prognosis group (survival X5 years;
n¼83) from the poor prognosis group (survival o5 years; n¼71),
the three-dimensional PCA (Figure 1C) and hierarchical clustering
analysis (Figure 1D) were performed. There were 24 peaks with
significant discriminatory value at distinguishing the good
prognosis group from the poor prognosis group. The 10 most
discriminating peaks were shown in Table 1B.
SAA was identified as differential protein
The overexpression of a protein peak at 11.6kDa was identified
as being significantly differentially expressed in both the
diagnosis and prognosis analysis. Two bar charts showed the
average normalised intensity of this peak’s overexpression in
the lung cancer sera (n¼154) when compared with the healthy
control sera (n¼35) (Figure 2A), and the overexpression in the
poor prognosis sera (n¼71) when compared with the good
prognosis sera (n¼83) (Figure 2B). The average normalised
intensity value was 19.2-fold higher (P¼1.75E 13) in the lung
cancer sera compared with that in the healthy control sera,
and the average expression of the sera from the poor prognosis
group was 1.8-fold higher (P¼3.27E 03) than the sera from
the good prognosis group. Using SDS-PAGE and tryptic
digestion followed by tandem MS fragmentation analysis, the
differential protein at 11.6kDa was identified as an isoform of
human SAA.
SAA validation by immunoassay
To validate the peak intensity on the SELDI-TOF-MS protein
profile with absolute concentrations determined by routine
method, the SAA concentration was measured by an immunoassay
kit in samples of both the lung cancer sera (n¼38) and the healthy
control sera (n¼34). The average SAA level was 41.7-fold higher
(P¼1.15E 06) in the lung cancer sera compared with that in the
healthy control sera (Figure 3).
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Figure 1 Multivariate analysis: three-dimensional principal components analysis (PCA) and hierarchical clustering analysis (red, upregulated; green,
downregulated). (A) PCA for healthy control (n¼35) vs lung cancer (n¼154). (B) Hierarchical clustering analysis for healthy control (n¼35) vs lung cancer
(n¼154). (C) PCA for patients with survival X5 years (n¼83) vs patients with survival o5 years (n¼71). (D) Hierarchical clustering analysis for patients
with survival X5 years (n¼83) vs patients with survival o5 years (n¼71).
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In the omics era, the development of high-throughput technologies
that permit the solution of deciphering cancer from higher
dimensionality provides a knowledge base that changes the face
of cancer understanding and therapeutics (Cho, 2010b). Serum is
one of the most easily procured patient specimens and it is
perceived to contain many of the molecules that might indicate
systemic function. Thus, serum is the sample source that is most
often profiled in the hopes of identifying sets of biomarkers for
clinical use (Gilbert et al, 2004).
In this study, proteomic analyses of serum samples from
patients with lung cancer and controls have identified SAA as an
elevated biomarker in lung cancer (as shown by SELDI analysis
and confirmed by immunoassay). It is known that SAA is secreted
during the acute phase of inflammation; the conservation of this
protein throughout invertebrates and vertebrates suggests that
SAA has an essential role in all animals including humans (Manley
et al, 2006). There are several functions of SAA protein, described
Table 1 The top 10 peaks best associated with diagnosis and prognosis ranked by P-value
Sample group Peak (m/z) Fraction Average peak intensity±s.e.m. Change P-value* AUC
(A)
Diagnostic biomarker: healthy control 11736 Organic 0.109±0.033 vs 1.872±0.212 1617% Up 7.02E 15 0.89
(n¼35) vs lung cancer (n¼154) 11563 Organic 0.078±0.012 vs 1.499±0.167 1822% Up 1.75E 13 0.88
51215 pH 4 0.327±0.010 vs 0.451±0.008 38% Up 3.12E 11 0.84
2789 pH 9 1.942±0.331 vs 5.418±0.318 179% Up 2.99E 09 0.80
7774 Organic 1.247±0.094 vs 2.115±0.069 70% Up 5.79E 09 0.79
5346 pH 7 1.251±0.182 vs 2.896±0.152 131% Up 1.09E 08 0.79
66646 pH 4 13.623±0.217 vs 15.204±0.122 12% Up 3.85E 08 0.77
17402 Organic 2.567±0.131 vs 1.664±0.056 35% Down 5.12E 09 0.82
133208 Organic 0.302±0.019 vs 0.175±0.007 42% Down 1.66E 09 0.82
13918 Organic 1.133±0.068 vs 0.722±0.026 36% Down 2.66E 08 0.80
(B)
Prognostic biomarker: patients with 11714 pH 7 1.489±0.206 vs 2.766±0.416 86% Up 2.87E 03 0.63
survival X5 years (n¼83) vs patients 11563 Organic 1.105±0.193 vs 1.959±0.275 77% Up 3.27E 03 0.63
with survival o5 years (n¼71) 11695 pH 4 0.753±0.124 vs 1.418±0.236 88% Up 9.01E 03 0.62
3892 pH 9 7.200±0.383 vs 4.788±0.320 34% Down 2.07E 05 0.71
17319 Organic 1.773±0.074 vs 1.411±0.066 20% Down 1.11E 03 0.65
3958 pH 9 7.707±0.960 vs 4.526±0.719 41% Down 1.47E 03 0.64
17577 pH 4 0.307±0.014 vs 0.245±0.015 20% Down 1.53E 03 0.65
3160 pH 9 7.795±0.933 vs 4.684±0.700 40% Down 2.18E 03 0.64
3975 pH 9 7.881±0.937 vs 4.243±0.589 46% Down 6.11E 03 0.62
4303 pH 9 7.720±0.868 vs 5.463±0.855 29% Down 7.85E 03 0.62
Abbreviations: AUC¼ area under the curve; m/z¼ mass/charge ratio; s.e.m.¼ standard error of the mean. *P-value from Mann–Whitney U-test between the comparable
groups.
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Figure 2 Univariate analysis. (A) Bar chart of potential diagnostic
biomarkers at m/z 11.6kDa for healthy control (n¼35) vs lung cancer
(n¼154). (B) Bar chart of potential prognostic biomarkers at m/z 11.6kDa
for patients with survival X5 years (n¼83) vs patients with survival o5
years (n¼71).
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Figure 3 Quantitative analysis of serum samples for serum amyloid A.
Bar chart of validation by immunoassay on serum amyloid A levels for
healthy control (n¼34) vs lung cancer (n¼38).
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sin the context of inflammation, that are compatible with the
mechanism of tumour invasion and metastasis. These properties
place SAA as an extracellular matrix-associated adhesion protein
with a potential role in tumour pathogenesis. The SAA mRNA
expression in epithelial cells was gradually increased as they
progressed through different stages of dysplasia to overt carcino-
ma (Gutfeld et al, 2006). Accumulating evidence has suggested that
SAA might be used to detect a pattern of physiological events that
reflect the growth of malignancy and host response. Elevated SAA
may be a primary product of tumour lesions, but can also be the
product of hepatocytes. Further investigation to determine
whether cancer tissue-derived cytokines stimulate SAA synthesis
in liver or epithelial cells will be interesting (Malle et al, 2009).
Overexpression of SAA has been reported in nasopharyngeal,
renal, gastric, hepatocellular, melanoma, breast, and endometrial
cancers (Cho et al, 2004; Tolson et al, 2004; Chan et al, 2007;
He et al, 2008; Findeisen et al, 2009; Pierce et al, 2009; Ramankulov
et al, 2008; Cocco et al, 2009, 2010; Sasazuki et al, 2010; Vermaat
et al, 2010). Our study not only detected increased SAA level in the
serum of lung cancer patients but also identified that elevated SAA
level may be a non-invasive biomarker, useful for the prediction of
lung cancer prognosis. As far as we know, the association of SAA
with the survival of lung cancer patients has never been reported.
Moreover, a number of SELDI peaks were found to be significantly
differentiated between the serum of cancer patients and controls,
as well as between the poor prognosis patients and good prognosis
patients. Further identification of these peaks is awaiting.
Recently, the US Food and Drug Administration has approved
an ovarian cancer triage test called OVA1, containing CA125 and
four biomarkers (b2-microglobulin, transferrin, apolipoprotein A1,
and transthyretin) identified by SELDI-TOF-MS (Fung, 2010). This
marks an encouraging step of translating biomarker discovery
from laboratory to clinic. It showed that having identified
biomarkers by primary screening, a standard assay may then be
developed and finally converted into clinically applicable mea-
sures. Our results reveal that the level of SAA is highly elevated in
lung cancer and in the patients with poor prognosis, thus
warranting further studies investigating this candidate biomarker
as part of a multimarker test for the diagnosis and prognosis of
lung cancer.
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